AR082111A1 - Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas - Google Patents
Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismasInfo
- Publication number
- AR082111A1 AR082111A1 ARP110102397A ARP110102397A AR082111A1 AR 082111 A1 AR082111 A1 AR 082111A1 AR P110102397 A ARP110102397 A AR P110102397A AR P110102397 A ARP110102397 A AR P110102397A AR 082111 A1 AR082111 A1 AR 082111A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- heterocycloalkyl
- alkyl
- haloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en la que: X es O ó S; Y es -C(O)- o -S(O)2-; A es un enlace sencillo o doble enlace, con la condición de que si X es S, entonces A sea un doble enlace; R1 es hidrógeno, alquilo C1-7, haloalquilo C1-7, alquenilo C2-7, alquinilo C2-7, cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con heterocicloalquilo, heteroarilo o -N(R6)2; dichos alquilo C1-7, haloalquilo C1-7, alquenilo C2-7 y alquinilo C2-7 están opcionalmente sustituidos de una a tres veces por R4 independientes; y dichos cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con heterocicloalquilo y heteroarilo están opcionalmente sustituidos de una a tres veces por R5 independientes; R2, R3 son con independencia hidrógeno, halógeno, alquilo C1-7, haloalquilo C1-7, hidroxi, alcoxi C1-7 o haloalcoxi C1-7; R4 es ciano, cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con heterocicloalquilo, heteroarilo, -C(O)N(R6)2, -N(R6)2, -NH(CO)-alquilo C1-7, hidroxi, alcoxi C1-7, haloalcoxi C1-7, oxo o -S(O)2R7, dichos cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con heterocicloalquilo y heteroarilo están opcionalmente sustituidos de una a tres veces por R5 independientes; R5 es halógeno, ciano, alquilo C1-7, haloalquilo C1-7, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, -C(O)N(R6)2, -N(R6)2, -NH(CO)-alquilo C1-7, hidroxi, alcoxi C1-7, haloalcoxi C1-7, oxo o -S(O)2R7, dichos cicloalquilo, heterocicloalquilo, arilo y heteroarilo están opcionalmente sustituidos de una a tres veces por sustituyentes elegidos con independencia entre el grupo formado por halógeno, ciano, alquilo C1-7, haloalquilo C1-7, hidroxi, alcoxi y oxo; R6 es hidrógeno o alquilo C1-7; R7 es hidrógeno, alquilo C1-7 o arilo, dicho arilo está opcionalmente sustituido de una a tres veces por sustituyentes elegidos con independencia entre el grupo formado por halógeno, ciano, alquilo C1-7, haloalquilo C1-7, hidroxi, alcoxi C1-7, haloalcoxi C1-7; y sus sales y ésteres farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10168490 | 2010-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR082111A1 true AR082111A1 (es) | 2012-11-14 |
Family
ID=44546276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110102397A AR082111A1 (es) | 2010-07-06 | 2011-07-05 | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas |
Country Status (14)
Country | Link |
---|---|
US (1) | US8470828B2 (es) |
EP (1) | EP2590984B1 (es) |
JP (1) | JP2013533872A (es) |
KR (1) | KR20130097149A (es) |
CN (1) | CN102958936B (es) |
AR (1) | AR082111A1 (es) |
BR (1) | BR112013000189A2 (es) |
CA (1) | CA2801583A1 (es) |
ES (1) | ES2533063T3 (es) |
HK (1) | HK1179964A1 (es) |
MX (1) | MX2012014135A (es) |
RU (1) | RU2013102401A (es) |
TW (1) | TW201206938A (es) |
WO (1) | WO2012004206A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009067493A2 (en) * | 2007-11-19 | 2009-05-28 | Envivo Pharmaceuticals, Inc. | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
KR20100135711A (ko) | 2007-12-20 | 2010-12-27 | 엔비보 파마슈티칼즈, 인코퍼레이티드 | 사중치환된 벤젠 |
US8586579B2 (en) * | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
AR095264A1 (es) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
CN106518841B (zh) * | 2015-09-15 | 2019-03-05 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
WO2017045599A1 (zh) * | 2015-09-15 | 2017-03-23 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
WO2018021447A1 (ja) | 2016-07-28 | 2018-02-01 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する含窒素縮環化合物 |
US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
EP3744721A4 (en) | 2018-01-26 | 2021-11-10 | Shionogi & Co., Ltd | CONDENSED CYCLIC COMPOUND WITH ANTAGONISM TO DOPAMINE D3 RECEPTOR |
CN113754580B (zh) * | 2020-06-05 | 2023-04-25 | 上海中泽医药科技有限公司 | 一种吡啶吗啉类化合物、其制备方法及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4596792B2 (ja) * | 2004-02-24 | 2010-12-15 | あすか製薬株式会社 | 5−ht1a作動作用と5−ht3拮抗作用を併有する薬剤 |
HUP0500170A3 (en) | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
RU2396265C2 (ru) | 2006-02-17 | 2010-08-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензоилпиперидина в качестве модуляторов рецепторов 5ht2 и d3 |
EP1870405A1 (en) | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
JP5502733B2 (ja) * | 2007-07-26 | 2014-05-28 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht2a及びd3受容体の二重のモジュレーター |
ES2366766T3 (es) | 2007-08-09 | 2011-10-25 | F. Hoffmann-La Roche Ag | Derivados de benzoílpiperidina como modulares duales de los receptores 5-ht2a y d3. |
BRPI0918949A2 (pt) | 2008-09-22 | 2019-09-24 | Hoffmann La Roche | moduladores de receptores de 5-ht2a e piperazina d3 |
WO2010034648A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors |
WO2010034646A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors |
CA2737252A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors |
US8586579B2 (en) * | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
-
2011
- 2011-06-29 US US13/171,499 patent/US8470828B2/en not_active Expired - Fee Related
- 2011-07-04 CA CA2801583A patent/CA2801583A1/en not_active Abandoned
- 2011-07-04 EP EP11728861.3A patent/EP2590984B1/en not_active Not-in-force
- 2011-07-04 BR BR112013000189A patent/BR112013000189A2/pt not_active IP Right Cessation
- 2011-07-04 MX MX2012014135A patent/MX2012014135A/es active IP Right Grant
- 2011-07-04 RU RU2013102401/04A patent/RU2013102401A/ru not_active Application Discontinuation
- 2011-07-04 KR KR1020137002990A patent/KR20130097149A/ko not_active Application Discontinuation
- 2011-07-04 ES ES11728861.3T patent/ES2533063T3/es active Active
- 2011-07-04 JP JP2013517324A patent/JP2013533872A/ja active Pending
- 2011-07-04 WO PCT/EP2011/061167 patent/WO2012004206A1/en active Application Filing
- 2011-07-04 CN CN201180031498.2A patent/CN102958936B/zh not_active Expired - Fee Related
- 2011-07-05 AR ARP110102397A patent/AR082111A1/es unknown
- 2011-07-05 TW TW100123741A patent/TW201206938A/zh unknown
-
2013
- 2013-06-21 HK HK13107236.4A patent/HK1179964A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US8470828B2 (en) | 2013-06-25 |
EP2590984A1 (en) | 2013-05-15 |
ES2533063T3 (es) | 2015-04-07 |
CA2801583A1 (en) | 2012-01-12 |
RU2013102401A (ru) | 2014-08-20 |
MX2012014135A (es) | 2013-01-29 |
HK1179964A1 (en) | 2013-10-11 |
TW201206938A (en) | 2012-02-16 |
JP2013533872A (ja) | 2013-08-29 |
CN102958936A (zh) | 2013-03-06 |
KR20130097149A (ko) | 2013-09-02 |
WO2012004206A1 (en) | 2012-01-12 |
CN102958936B (zh) | 2015-10-21 |
BR112013000189A2 (pt) | 2016-05-24 |
EP2590984B1 (en) | 2015-01-28 |
US20120010201A1 (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
AR082004A1 (es) | Compuestos de fusion de piridina | |
AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR081577A1 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
PE20160661A1 (es) | Compuesto de azapiridona y sus usos de los mismos | |
AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
ES2640911T3 (es) | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus | |
AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
CO6361937A2 (es) | Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
AR078756A1 (es) | Moduladores alostericos positivos (map) | |
CO6020016A1 (es) | Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |